Cargando…

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

PURPOSE: To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation (CRT) in unresectable pancreatic cancer. METHODS: Seventeen patients with CT-staged, biopsy-proven unresectable pancreatic cancer w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chadha, Awalpreet S., Skinner, Heath D., Gunther, Jillian R., Munsell, Mark F., Das, Prajnan, Minsky, Bruce D., Delclos, Marc E., Chatterjee, Deyali, Wang, Huamin, Clemons, Marilyn, George, Geena, Singh, Pankaj K., Katz, Matthew H., Fleming, Jason B., Javle, Milind M., Wolff, Robert A., Varadhachary, Gauri R., Crane, Christopher H., Krishnan, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919049/ https://www.ncbi.nlm.nih.gov/pubmed/27336466 http://dx.doi.org/10.1371/journal.pone.0156910

Ejemplares similares

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
por: Das, Prajnan, et al.
Publicado: (2006)

A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer
por: Gunther, Jillian R., et al.
Publicado: (2022)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Reirradiation to the abdomen for gastrointestinal malignancies
por: Haque, Waqar, et al.
Publicado: (2009)

Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC
por: Colbert, Lauren E., et al.
Publicado: (2017)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
por: Javle, M, et al.
Publicado: (2009)

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma
por: SAIF, MUHAMMAD WASIF, et al.
Publicado: (2014)

Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
por: Koay, Eugene J., et al.
Publicado: (2019)

Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer
por: Moningi, Shalini, et al.
Publicado: (2022)

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
por: Javle, Milind M, et al.
Publicado: (2010)

Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer
por: Ziemons, Janine, et al.
Publicado: (2023)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review
por: Taherian, Mehran, et al.
Publicado: (2022)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
por: Chen, Ming-Huang, et al.
Publicado: (2016)

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study
por: Jackson, Christopher GCA, et al.
Publicado: (2014)

Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy
por: De, Brian, et al.
Publicado: (2021)

A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer
por: Sanghvi, Samrat M., et al.
Publicado: (2022)

Adding Consolidation Capecitabine to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Propensity-Matched Comparative Study
por: Fang, Yifang, et al.
Publicado: (2022)

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
por: Fogelman, David R., et al.
Publicado: (2014)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei
por: Farquharson, A L, et al.
Publicado: (2008)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022)

Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis
por: Gunther, Jillian R., et al.
Publicado: (2017)

Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma
por: Mok, Henry, et al.
Publicado: (2011)

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
por: Thatcher, Nicholas, et al.
Publicado: (2010)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study
por: Sheng, Xue-Qing, et al.
Publicado: (2022)

Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
por: Amer, Ahmed M., et al.
Publicado: (2018)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network
por: Augustyn, Alexander, et al.
Publicado: (2021)

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
por: Fang, Xuefeng, et al.
Publicado: (2023)

Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
por: ZHANG, JIAN, et al.
Publicado: (2012)

Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes
por: Raghav, Kanwal, et al.
Publicado: (2016)

Updates in Gastrointestinal Oncology – insights from the 2008 44(th )annual meeting of the American Society of Clinical Oncology
por: Javle, Milind, et al.
Publicado: (2009)

Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology
por: Javle, Milind, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7kg089iaqeganl4kvgrn0hah7m